Beacon Biosignals develops an EEG-based neurobiomarker platform for precision medicine in neurology and psychiatry. Its core offering provides quantitative assessments of how treatments affect EEG and sleep data to speed up clinical trials and inform dose selection. By analyzing EEG signals alongside PK/PD relationships, the platform helps identify dosing that achieves the best balance of efficacy and safety, supporting the development of new therapies. The company differentiates itself through its proprietary EEG biomarkers and a focus on integrating brain activity data into trial design, enabling closer monitoring of treatment impact for biopharma, academic medical centers, and neurotechnology developers. Beacon Biosignals aims to advance personalized treatment for neurological and psychiatric diseases and improve the efficiency of clinical development in precision medicine.
Company Size
51-200
Company Stage
Series B
Total Funding
$127.5M
Headquarters
Boston, Massachusetts
Founded
2019
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?